Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine

Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine

<b><i>Background:</i></b> Anthracyclines such as doxorubicin remain a primary treatment for hematological malignancies and breast cancers. However, cardiotoxicity induced by anthracyclines, possibly leading to heart failure, severely limits their application. The pathological...

Full description

Bibliographic Details
Main Authors: Irwin K. Cheah, Richard M. Y. Tang, Xiaoyuan Wang, Karishma Sachaphibulkij, Suet Yen Chong, Lina H. K. Lim, Jiong-Wei Wang, Barry Halliwell
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Antioxidants
Subjects:
ergothioneine
doxorubicin
cardiotoxicity
anthracycline
chemotherapy
Online Access:https://www.mdpi.com/2076-3921/12/2/320

Internet

https://www.mdpi.com/2076-3921/12/2/320

Similar Items